RxDoctor Payments Data

Joseph Nkwanyuo, MD

Internal Medicine · Randallstown, MDNPI 1194805036

Payments from drug & device makers

$1,327in general payments, 2019–2025

Across 77 payments — averaging $17.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$208
  • Novo Nordisk$163
  • Amarin Pharma, Inc.$160
  • AbbVie$140
  • AstraZeneca$115
  • Novartis$82
  • plus $460 from 14 others

What the payments were for

  • Food & beverage$1,28997%
  • Education$383%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,327 in reported general payments places this provider in the 75th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$39,505
Medicare patients
47
Services billed
258

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala39$151,579
GenvoyaElviteg/Cob/Emtri/Tenof Alafen33$133,723
JardianceEmpagliflozin59$93,732
Janumet XrSitagliptin Phos/Metformin Hcl33$45,417
EliquisApixaban22$33,641
XareltoRivaroxaban24$23,661
JanuviaSitagliptin Phosphate20$17,142
OzempicSemaglutide15$14,342
MyrbetriqMirabegron23$13,801
Tresiba Flextouch U-200Insulin Degludec19$12,682
LinzessLinaclotide17$10,563
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,581
Combivent RespimatIpratropium/Albuterol Sulfate13$6,188
Oxycodone Hcl238$3,946
Fluticasone-SalmeterolFluticasone Propion/Salmeterol22$3,500

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya$35$285,30272 claims
Boehringer IngelheimJardiance, Combivent Respimat$208$99,92072 claims
MerckJanumet Xr, Januvia$73$62,55953 claims
PfizerEliquis$15$33,64122 claims
Novo NordiskOzempic$163$14,34215 claims
Astellas Pharma US IncMyrbetriq$51$13,80123 claims
AbbVieLinzess$140$10,56317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Randallstown

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →